Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

American College of Cardiology Meeting In Brief: Roche's mibefradil

Executive Summary

Roche's mibefradil: In the dose-ranging Mibefradil Ischemia Suppression Trial (MIST) in patients with coronary artery disease and angina, mibefradil significantly increased the time to onset of angina in exercising patients, Dan Tzivoni, MD, Shaare Zedek Medical Center, Jerusalem, reported March 26. Mibefradil additionally increased exercise duration by 11%-24% at different doses, reduced the number of ischemic episodes by 65%-74%, reduced the duration of ischemia by 64%-75% and reduced maximum ST depressions by 50%-62%. Mibefradil is in Phase III in the U.S...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel